{
    "id": "dbpedia_8203_0",
    "rank": 82,
    "data": {
        "url": "https://www.visiongain.com/report/top-55-pharma-cmos-market-2020/",
        "read_more_link": "",
        "language": "en",
        "title": "Top 55 Pharmaceutical Contract Manufacturing Organisations",
        "top_image": "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
        "meta_img": "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
        "images": [
            "https://www.visiongain.com/wp-content/uploads/2024/08/Visiongain-Logo-Updates.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2020/07/COVID5.png",
            "https://www.visiongain.com/wp-content/uploads/2020/01/Charles-River-Financial-Performance.jpg",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Generic-Web-Cover-DW-V01.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Credit-Cards-26.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Kelloggs_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/3m_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Thales_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/TEVA_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Shell_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Raytheon_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Pfizer_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Lockheed-Martin_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Halliburton_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Honeywell_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Du-Pont_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Daimler_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BP_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Bayer_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BASF_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BAE-Systems_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Unilever_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Kelloggs_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/3m_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Thales_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/TEVA_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Shell_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Raytheon_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Pfizer_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Lockheed-Martin_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Halliburton_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Honeywell_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Du-Pont_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Daimler_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BP_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Bayer_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BASF_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/BAE-Systems_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/wp-responsive-images-thumbnail-slider/Unilever_120_215.png",
            "https://www.visiongain.com/wp-content/uploads/2024/07/Credit-Cards-26.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "contract pharmaceutical manufacturing",
            "outsourced pharma manufacturing",
            "contract manufacturing organisation (CMO)",
            "contract development and manufacturing organisation (CDMO)",
            "contract research and manufacturing services (CRAMS)",
            "biopharmaceutical manufacturing",
            "bulk drug manufacturing",
            "active pharmaceutical ingredient (API)",
            "highly potent APIs (HPAPIs)",
            "finished dosage forms (FDFs)",
            "generic drugs",
            "cytotoxic drugs",
            "biological drugs",
            "monoclonal antibodies",
            "antibody-drug conjugates (ADCs)",
            "biosimilar drugs",
            "oral drugs",
            "solid dosage forms",
            "liquid drugs",
            "injectables",
            "parenteral manufacturing",
            "lyophilisation",
            "sterile drugs",
            "aseptic filling",
            "hot-melt extrusion",
            "granulation",
            "pre-formulation",
            "formulation development",
            "reformulation",
            "product characterisation",
            "stability studies",
            "scale-up",
            "pilot-scale manufacturing",
            "contract manufacturing",
            "pharmaceutical development services",
            "CMO",
            "HPAPI",
            "high potency active pharmaceutical ingredients",
            "ADCs",
            "antibody-drug conjugates",
            "cytotoxic",
            "drug manufacturing",
            "finished dosage formulation",
            "aseptic filing",
            "pre-filed syringes",
            "lyophilisation",
            "pharmaceutical outsourcing",
            "clinical trial supply",
            "capsule filing",
            "biopharmaceutical manufacturing",
            "disposable bio-reactors",
            "fill and finish",
            "ampoules",
            "vials",
            "freeze drying",
            "excipients",
            "APIs",
            "SWOT analysis",
            "competitive intelligence",
            "profitability forecast",
            "revenue forecast",
            "full-service CMO",
            "mergers & acquisitions",
            "CRAMS",
            "contract research and manufacturing services",
            "drug formulation",
            "commercial development",
            "drug reformulation",
            "pharmaceutical life-cycle management",
            "primary packaging",
            "stability studies",
            "product characterization",
            "drug safety analysis",
            "cGMP",
            "spray drying",
            "custom research",
            "consulting services",
            "industry reports",
            "research services",
            "market research reports",
            "global industry analysis",
            "research methodology",
            "evidence-based insights",
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Who are the leading pharmaceutical contract manufacturers? What factors are driving and restraining the growth for leading CMOs? Find out in our market report of 2020.",
        "meta_lang": "en",
        "meta_favicon": "”https://www.visiongain.com/favicon.ico”",
        "meta_site_name": "Visiongain Reports",
        "canonical_link": "https://www.visiongain.com/report/top-55-pharma-cmos-market-2020/",
        "text": "1. Report Overview\n\n1.1 Leading Contract Manufacturing Organisations (CMOs) Overview\n\n1.2 Benefits of This Report\n\n1.3 How This Report Delivers Information\n\n1.4 Main Questions This Report Answers\n\n1.5 Who is This Report For?\n\n1.6 Methods of Research and Analysis\n\n1.7 Frequently Asked Questions (FAQs)\n\n1.8 Some Associated Reports\n\n1.9 About Visiongain\n\n2. Introduction to Pharmaceutical Contract Manufacturing, 2019\n\n2.1 What Services Do Contract Manufacturers Offer?\n\n2.1.1 Why Do Firms Outsource Manufacturing?\n\n2.1.2 What Is Driving Demand for Contract Manufacturing Services?\n\n2.2 The Pharmaceutical Contract Manufacturing Market, 2019\n\n2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?\n\n2.3 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing\n\n2.3.1 Pharmaceutical Contract Manufacturing: Market Drivers\n\n2.3.2 Pharmaceutical Contract Manufacturing: Market Restraints\n\n3. Leading Contract Manufacturing Organisations\n\n3.1 Alcami Corporation – A Contract Development and Manufacturing Organization\n\n3.1.1 Alcami: Manufacturing Services and Capabilities\n\n3.1.2 Divisional Segmentation – Breakdown of Alcami’s Service\n\n3.1.3 Alcami Focuses on Advancing its Analytical Testing Turnaround Time\n\n3.1.4 Alcami Extended its Laboratory Service Program\n\n3.1.5 Alcami: Madison Dearborn Partners\n\n3.1.6 Alcami Expands its Sales Office\n\n3.1.7 Alcami Partnered with Solasia Pharma for Manufacturing Active Pharmaceutical Ingredient\n\n3.2 AbbVie Contract Manufacturing\n\n3.2.1 AbbVie Offers Full-Service Contract Manufacturing\n\n3.2.2 Expanding and Adding New Services: 2018-2019\n\n3.2.3 Biologics and HPAPIs Are Opportunities for Growth\n\n3.3 Aenova Group\n\n3.3.1 Acquisition of Haupt Creates European CMO Giant\n\n3.3.2 Aenova’s Ever Expanding Manufacturing Capacity\n\n3.3.3 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis\n\n3.3.4 Aenova: New Manufacturing Facilities to Expand Geographic Presence\n\n3.4 Aesica Pharmaceuticals\n\n3.4.1 Aesica Manufactures APIs and Finished Dosage Forms\n\n3.4.2 Acquisitions Drive Revenue Growth\n\n3.4.3 Partnering with Academia for Innovative Solutions\n\n3.4.4 Growth through Acquisitions and Internal Expansion\n\n3.4.5 Aesica: Opportunities for Expansion\n\n3.5 Ajinomoto Althea, Inc.\n\n3.5.1 Ajinomoto Althea Expands its Manufacturing Capabilities\n\n3.5.2 Ajinomoto: New U.S. Patent for Manufacturing Crystal Monoclonal Antibodies\n\n3.5.3 Ajinomoto Althea Expanding its Manufacturing Capacity\n\n3.6 Albany Molecular Research, Inc.\n\n3.6.1 Acquiring New Businesses to Expand Capabilities and Services\n\n3.6.2 Expanding Business Operations in New Geographies\n\n3.6.3 Collaborations to Enhance Services\n\n3.6.4 AMRI Acquisition of Euticals S.p.a\n\n3.7 Alkermes\n\n3.7.1 Collaboration as a Growth Strategy to Develop and Commercialize Products\n\n3.7.2 Alkermes: Clinical Development Program\n\n3.8 Almac Group\n\n3.8.1 Almac’s Manufacturing Services\n\n3.8.2 Almac Adding Capacity Globally\n\n3.8.3 New Services Added\n\n3.8.4 Almac Group: Contract Manufacturing Market Outlook\n\n3.9 Amatsigroup (Eurofin Amtasigroup)\n\n3.9.1 Amatsi: Contract Manufacturing Agreement\n\n3.9.2 Mergers and Acquisitions to Enhance Market Presence\n\n3.9.3 Amatsigroup Expands its Operations and Product Portfolio\n\n3.10 Aurobindo Pharma\n\n3.10.1 API Manufacturing Services\n\n3.10.2 Aurobindo Pharma: Steady Revenue Growth 2012-2017\n\n3.10.3 Aurobindo Expanding Outside of Antibacterial\n\n3.10.4 Aurobindo: Opportunities for Expansion\n\n3.11 Avid Bioservices, Inc.\n\n3.11.1 Avid Focuses on Expanding its Manufacturing Capacity\n\n3.11.2 Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture\n\n3.11.3 Avid Bioservices Expands Process Development Capabilities and Laboratory Infrastructure\n\n3.12 Bayer Healthcare AG\n\n3.12.1 Bayer Focuses on Providing Superior Pharmaceutical Services\n\n3.12.2 Bayer Focuses Quality for all the Products and Services Offered by the Company\n\n3.12.3 Bayer Pharmaceuticals main focus areas\n\n3.12.4 Bayer’s Vision 2020\n\n3.13 Baxter BioPharma Solutions\n\n3.13.1 BioPharma Solutions Offers a Broad Product Portfolio of Sterile Contract Manufacturing Services and Solutions\n\n3.13.2 BioPharma Focuses on Expanding its Manufacturing Capacities\n\n3.13.3 Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering\n\n3.13.4 Baxter BioPharma Solutions Focuses on Research & Development Investments\n\n3.13.5 Baxter BioPharma is the Global Leader in Sterile Fill and Finish\n\n3.13.6 Baxter BioPharma SWOT Analysis\n\n3.14 Biomay AG\n\n3.14.1 Biomay Offers Fully Integrated GMP Capacities\n\n3.14.2 Biomay Focuses on Increasing its Capital\n\n3.15 Boehringer Ingelheim Contract Manufacturing\n\n3.15.1 BI Existing Units and Expansion to new areas\n\n3.15.2 Production Through to Fill and Finished Biopharmaceuticals\n\n3.15.3 A Track Record of Production for 29 Biopharma Products\n\n3.15.4 Increasing Revenue from Contract Manufacturing, 2012-2019\n\n3.15.5 Pulling Out of Small Molecule API Manufacturing\n\n3.15.6 Expanding through New Services\n\n3.15.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth\n\n3.16 Catalent Pharma Solutions - the World’s Leading CMO\n\n3.16.1 Catalent: Manufacturing Services and Capabilities\n\n3.16.2 Divisional Segmentation – Catalent’s Service\n\n3.16.3 Catalent Pharma’s Revenue Growth, 2014-2019\n\n3.16.4 Catalent Is Expanding its Softgel Technologies Division\n\n3.16.5 Quadrupling Biopharmaceutical Manufacturing Capacity\n\n3.16.6 Expansion of Packaging Services in Asia-Pacific and Europe: 2018\n\n3.16.7 Adding New Early-Stage Development Services\n\n3.16.8 Expansion in Japan – Growth Prospects for Catalent\n\n3.16.9 New Business Contracts 2014-2019\n\n3.16.10 Catalent: Opportunities for Growth\n\n3.17 Charles River Laboratories International, Inc.\n\n3.17.1 Charles River Laboratories Focuses on Increasing the Service Areas of its Offerings\n\n3.17.2 Strategic Acquisitions as a Growth Strategy to Expand Product Portfolio\n\n3.17.3 Charles River Laboratories Revenue Growth, 2013-2018\n\n3.18 Cardinal Health, Inc.\n\n3.18.1 Cardinal Health Focuses on Helping Healthcare Organizations for Patient Safety\n\n3.18.2 Cardinal Revenue Growth, 2013-2018\n\n3.19 CordenPharma International\n\n3.19.1 CordenPharma Service Division\n\n3.19.2 CordenPharma Emerging in the API Market\n\n3.19.3 Investments in Highly Potent Capabilities\n\n3.19.4 CordenPharma: SWOT Analysis\n\n3.20 Daito Pharmaceutical Co., Ltd.\n\n3.20.1 Daito Has a Portfolio of More than 43 APIs\n\n3.20.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2013-2018\n\n3.20.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis\n\n3.21 Delpharm\n\n3.21.1 Finished Dosage Form Manufacturing for Developed Markets\n\n3.21.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2013-2019\n\n3.21.3 Delpharm: Outlook and Prospects for Growth\n\n3.22 Divis Laboratories\n\n3.22.1 Divis Laboratories and the Contract Manufacturing Industry\n\n3.22.2 Divis Laboratories: A Rapidly Growing CMO, 2014-2019\n\n3.22.3 Divis Laboratories: API Manufacturing\n\n3.23 Dr. Reddy’s Laboratories Ltd.\n\n3.23.1 API and FDF Manufacturing Services\n\n3.23.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2012-2017\n\n3.23.3 Advancing in Complex Drug Manufacturing\n\n3.23.4 Expanding in the European Manufacturing Market\n\n3.24 DPT Laboratories, Ltd.\n\n3.24.1 Mylan Acquires Topicals-Focused Specialty and Generic Business of DPT\n\n3.24.2 DPT Enhances Flexibility and Efficiencies\n\n3.24.3 DPT Enhances Capabilities with New High-Speed Filling Center\n\n3.25 Esteve Qu`mica\n\n3.25.1 Esteve Química Manufactures APIs for Developed and Emerging Markets\n\n3.25.2 Expanding in the US, 2018\n\n3.25.3 Esteve Química: SWOT Analysis\n\n3.26 Evonik Degussa\n\n3.26.1 Investing in API and Drug Delivery Services\n\n3.26.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2013-2018\n\n3.26.3 Evonik Is a HPAPI Specialist\n\n3.26.4 Evonik Continues to Grow Across All Segments\n\n3.26.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?\n\n3.27 FAMAR Health Care Services\n\n3.27.1 Famar Is an Expert in Lyophilisation\n\n3.27.2 Sustained Growth in Famar’s Revenue\n\n3.27.3 Expanding Outside Europe\n\n3.27.4 Further Site Acquisitions Are an Opportunity for Growth\n\n3.28 Fareva Group\n\n3.28.1 Fareva Has 35 Years’ Manufacturing Experience\n\n3.28.2 Revenue Growth through Acquisitions:\n\n3.28.3 Fareva SWOT Analysis\n\n3.29 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.\n\n3.29.1 Opening of New Manufacturing facility\n\n3.29.2 Fujifilm Establishes Cell Culture Process Development Laboratories\n\n3.29.3 Fujifilm Completes Acquisition of Kalon Biotherapeutics LLC\n\n3.30 GlaxoSmithKline plc\n\n3.30.1 GSK Enters into an Agreement with Novartis for Full Ownership of Consumer Healthcare Business\n\n3.30.2 GSK Received Complete Response from FDA for Candidate Pandemic H5N1 Adjuvanted Influenza Vaccine\n\n3.31 Pfizer CentreOne\n\n3.31.1 Pfizer CentreSource: Historic Revenue Performance, 2012-2017\n\n3.31.2 Will Hospira Acquisition Lead to Revenue Growth in Future?\n\n3.32 Huapont Pharmaceutical Co., Ltd.\n\n3.32.1 China Pharmaceutical Trade\n\n3.33 Lonza\n\n3.33.1 Lonza Is a Leader in Biologics Manufacturing\n\n3.33.2 Lonza Contract Manufacturing and Development\n\n3.33.3 Investing in Advanced Biological Drug Sectors\n\n3.33.4 The Promise of Antibody-Drug Conjugates (ADCs)\n\n3.33.5 The Regenerative Medicine Future in Japan\n\n3.33.6 Lonza: SWOT Analysis\n\n3.34 Nipro Corporation: Japan’s Leading CMO\n\n3.34.1 Nipro Pharmaceutical Contract Manufacturing Capabilities\n\n3.34.2 Nipro Revenues 2014-2019\n\n3.34.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis\n\n3.35 Paragon Bioservices, Inc.\n\n3.35.1 Paragon Announced Expansion of its New Manufacturing Facility\n\n3.36 Patheon – One of the Top 3 CMOs\n\n3.36.1 Patheon – Global leader in Pharmaceutical Development Services\n\n3.36.2 Contract Manufacturing Services at Patheon\n\n3.36.3 Steady Revenue Growth 2012-2017\n\n3.36.4 DPx Holdings: Developments\n\n3.36.5 Adding New Formulations and Formulation Development Services\n\n3.36.6 Expanding Services Through Acquisition, 2016\n\n3.36.7 Patheon: SWOT Analysis\n\n3.37 Recipharm\n\n3.37.1 Contract Development and Manufacturing Services\n\n3.37.2 Recipharm: Financial Performance 2013-2018\n\n3.37.3 Recipharm Invests in Facility Expansion\n\n3.37.4 Recipharm Growing in the Development and Technology Market Through Acquisitions\n\n3.37.5 Recipharm: SWOT Analysis\n\n3.38 F. Hoffman-La Roche Ltd.\n\n3.38.1 Amplified Revenue Growth in Pharma Manufacturing 2012-2017\n\n3.38.2 Value of Innovation\n\n3.38.3 Approvals and Extensions in Pharmaceuticals Division\n\n3.38.4 Launch of New Products Drive the Growth of the Company\n\n3.39 Royal DSM\n\n3.39.1 Amplified Revenue Growth in Pharma Manufacturing 2013-2018\n\n3.39.2 DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services\n\n3.39.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing\n\n3.39.4 DPx Holdings: A New Pharma Leader\n\n3.39.5 Investing in Biopharma Manufacturing\n\n3.39.6 Expanding API Manufacturing\n\n3.39.7 Generics and Biologics Offer Room for Growth\n\n3.40 Shandong Xinhua Pharmaceutical\n\n3.40.1 Experience in APIs and Finished Dosage Forms\n\n3.40.2 Shandong Xinhua: Strong Revenue Growth 2013-2018\n\n3.40.3 Growing through Joint Ventures\n\n3.40.4 Looking to Expand in the US and EU\n\n3.41 Siegfried\n\n3.41.1 Siegfried’s Acquisitions, 2013-2019\n\n3.41.2 Expanding Siegfried’s Manufacturing Footprint Globally\n\n3.41.3 Expanding High Potency API Capabilities\n\n3.41.4 Siegfried: Financial Performance 2013-2018\n\n3.41.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis\n\n3.42 TEVA Pharmaceutical, Ltd.\n\n3.42.1 API Manufacturing Services\n\n3.42.2 Teva API: Financial Performance 2012-2017\n\n3.42.3 Building a Footprint in Mexico, India and China\n\n3.42.4 Teva API: SWOT Analysis\n\n3.43 Therapure Biopharma, Inc.\n\n3.43.1 Therapure Collaborated with 3SBio Inc., and CPE Funds\n\n3.44 UPM Pharmaceuticals\n\n3.45 Vetter Pharmaceutical\n\n3.45.1 Vetter is an Injectable Manufacturing Specialist\n\n3.45.2 Services, Collaborations and Differentiating Factors\n\n3.45.3 Expanding Services in the US and Asia\n\n3.45.4 Biologics: Opportunity for Growth for Vetter\n\n3.46 Xcelience, LLC (Acquired by Capsugel)\n\n3.47 Samsung Biologics Inc.\n\n3.47.1 Samsung Biologics, The Growth Factor\n\n3.47.2 Samsung Biologics, Financial Overview\n\n3.47.3. Samsung Biologics, SWOT\n\n3.48 Piramal Pharma Solutions\n\n3.48.1 Mergers and Acquisitions\n\n3.48.2 Piramal Pharma Solutions: Financial Performance 2013-2018\n\n3.48.3 Investment in Technology-based Delivery Platforms\n\n3.48.4 Quality Governance\n\n3.49 Zhejiang Hisun Pharmaceutical\n\n3.49.1 API Manufacturing for Markets Worldwide\n\n3.49.2 Moving into International Drug Marketing\n\n3.49.3 Zhejiang Hisun: Opportunities for Growth\n\n3.50 Zhejiang Huahai Pharmaceuticals\n\n3.50.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market\n\n3.50.2 Zhejiang Huahai: Contract Manufacturing Performance 2012-2017\n\n3.50.3 Expanding in the US Generic Drugs Market\n\n3.50.4 Zhejiang Huahai: SWOT Analysis\n\n3.51 Cambrex Corporation\n\n3.51.1 Cambrex acquisition by Permira in 2019\n\n3.51.2 Revenue growth of Cambrex Corporation 2014-2018\n\n3.51.3 Cambrex Corporation SWOT Analysis\n\n3.52 WuXi Pharma tech\n\n3.52.1 WuXi Tech strategies for development\n\n3.52.2 WuXi Tech SWOT analysis\n\n3.53 Biocon\n\n3.53.1 Biocon Revenue Analysis 2013-2018\n\n3.53.2 Merger and Acquisition a leading strategy for Biocon\n\n3.53.3 SWOT Analysis of Biocon\n\n3.54 Strides\n\n3.54.1 Revenue of Stride 2014-2019\n\n3.54.2 Strides – SWOT Analysis\n\n3.55 Biophore\n\n3.55.1 Biophore Development in API production\n\n4. Conclusions of the Study\n\n4.1 What Has Driven Growth for CMO Market Leaders in Recent Years?\n\n4.2 Strategies for Growth: Prospects for Leading CMOs\n\n4.3 High Demand for Biopharmaceutical Manufacturing Services\n\n4.4 Investing in Novel Technologies\n\n4.5 Outlook for API Manufacturers\n\nAppendices\n\nSome Associated Visiongain Reports\n\nVisiongain Report Sales Order Form\n\nAbout Visiongain\n\nVisiongain Report Evaluation Form\n\nList of Tables\n\nTable 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2020\n\nTable 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2016-2018\n\nTable 2.3 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2018\n\nTable 3.1 Alcami Details\n\nTable 3.2 Alcami Facility Details\n\nTable 3.3 AbbVie Contract Manufacturing: Details\n\nTable 3.4 AbbVie Contract Manufacturing Facility Capabilities\n\nTable 3.5 AbbVie Contract Manufacturing SWOT Analysis\n\nTable 3.6 Aenova Group Details\n\nTable 3.7 Aenova Group Manufacturing Capacity by Dosage Form\n\nTable 3.8 Aenova Group Manufacturing Facility Details\n\nTable 3.9 Aenova Group SWOT Analysis\n\nTable 3.10 Aesica Details\n\nTable 3.11 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019\n\nTable 3.12 Aesica SWOT Analysis\n\nTable 3.13 Ajinomoto Althea, Inc. Details\n\nTable 3.14 Albany Molecular Research, Inc. Details\n\nTable 3.15 Alkermes Details\n\nTable 3.16 Almac Details\n\nTable 3.17 Almac Pharmaceutical Manufacturing Facilities Details\n\nTable 3.18 Almac: SWOT Analysis\n\nTable 3.19 Amatsigroup Details\n\nTable 3.20 Aurobindo Pharma Details\n\nTable 3.21 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2018\n\nTable 3.22 Aurobindo Contract Manufacturing: SWOT Analysis\n\nTable 3.23 Avid Bioservices, Inc. Details\n\nTable 3.24 Bayer Healthcare AG Details\n\nTable 3.25 Baxter BioPharma Solutions Details\n\nTable 3.26 Baxter BioPharma Solutions: Facilities and Services Offered\n\nTable 3.27 Baxter BioPharma Solutions SWOT Analysis\n\nTable 3.28 Biomay AG Details\n\nTable 3.29 Boehringer Ingelheim Biopharmaceuticals Details\n\nTable 3.30 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service\n\nTable 3.31 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014\n\nTable 3.32 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2018\n\nTable 3.33 Boehringer Ingelheim: SWOT Analysis\n\nTable 3.34 Catalent Details\n\nTable 3.35 Catalent Facility Details\n\nTable 3.36 Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2014-2019\n\nTable 3.37 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2019\n\nTable 3.38 Catalent Pharma SWOT Analysis\n\nTable 3.39 Charles River Laboratories International, Inc. Details\n\nTable 3.40 Charles River Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2013-2018\n\nTable 3.41 Cardinal Health, Inc. Details\n\nTable 3.42 Cardinal Health Financial Performance: Revenue ($b), Annual Growth Rates (%), CAGR (%), 2013-2018\n\nTable 3.43 CordenPharma International Details\n\nTable 3.44 CordenPharma Facilities and Service Details\n\nTable 3.45 CordenPharma SWOT Analysis\n\nTable 3.46 Daito Pharmaceutical: Details\n\nTable 3.47 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), CAGR (%), 2013-2018\n\nTable 3.48 Daito Pharmaceuticals SWOT Analysis\n\nTable 3.49 Delpharm Details\n\nTable 3.50 Delpharm: Facilities and Services\n\nTable 3.51 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2018\n\nTable 3.52 Delpharm: SWOT Analysis\n\nTable 3.53 Divis Laboratories Details\n\nTable 3.54 Divis Laboratories: Facility Details, Production Capacity and Services\n\nTable 3.55 Divis Laboratories: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.56 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2018\n\nTable 3.57 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2018\n\nTable 3.58 Divis Laboratories Contract Manufacturing: SWOT Analysis\n\nTable 3.59 Dr. Reddy’s Laboratories Ltd. Details\n\nTable 3.60 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 2017\n\nTable 3.61 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2019\n\nTable 3.62 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2019\n\nTable 3.63 Dr. Reddy’s Laboratories: SWOT Analysis\n\nTable 3.64 DPT Laboratories Ltd. Details\n\nTable 3.65 Esteve Química Details\n\nTable 3.66 Esteve Química SWOT Analysis\n\nTable 3.67 Evonik Degussa Details\n\nTable 3.68 Evonik Health and Nutrition: R&D and Production Sites by Region, 2018\n\nTable 3.69 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2018\n\nTable 3.70 Evonik Pharmaceutical Manufacturing: SWOT Analysis\n\nTable 3.71 Famar Details\n\nTable 3.72 Famar Pharmaceutical Manufacturing Facilities\n\nTable 3.73 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.74 Famar: SWOT Analysis\n\nTable 3.75 Fareva Details\n\nTable 3.76 Fareva Manufacturing Facilities\n\nTable 3.77 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.78 Fareva: SWOT Analysis\n\nTable 3.79 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Details, 2017\n\nTable 3.80 GlaxoSmithKline plc Details\n\nTable 3.81 Pfizer CentreOne Details\n\nTable 3.82 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017\n\nTable 3.83 Pfizer CentreOne SWOT Analysis\n\nTable 3.84 Huapont Pharmaceutical Co., Ltd. Details\n\nTable 3.85 Lonza Details\n\nTable 3.86 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements\n\nTable 3.87 Lonza Pharma & Biotech Department: Revenue ($m), 2013-2018\n\nTable 3.88 ADCs Approved and in Late Stage Clinical Development\n\nTable 3.89 Lonza SWOT Analysis, 2019\n\nTable 3.90 Nipro Pharma Details\n\nTable 3.91 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2012-2017\n\nTable 3.92 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2018\n\nTable 3.93 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2014-2019\n\nTable 3.94 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis\n\nTable 3.95 Paragon Bioservices, Inc. Details\n\nTable 3.96 Patheon Details\n\nTable 3.97 Patheon Manufacturing Facilities\n\nTable 3.98 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017\n\nTable 3.99 Patheon: SWOT Analysis\n\nTable 3.100 Recipharm Details\n\nTable 3.101 Recipharm: Facility Details and Services\n\nTable 3.102 Recipharm: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2013-2018\n\nTable 3.103 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2018\n\nTable 3.104 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2018\n\nTable 3.105 Recipharm: SWOT Analysis\n\nTable 3.106 F. Hoffman-La Roche Details\n\nTable 3.107 Roche Pharmaceutical Manufacturing: Revenue ($bn), Annual Growth (%), CAGR (%) 2013-2018\n\nTable 3.108 Royal DSM Details\n\nTable 3.109 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2012-2018\n\nTable 3.110 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016\n\nTable 3.111 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017\n\nTable 3.112 DSM Pharmaceutical Manufacturing: SWOT Analysis\n\nTable 3.113 Shandong Xinhua Pharmaceuticals Details\n\nTable 3.114 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2018\n\nTable 3.115 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.116 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2018\n\nTable 3.117 Shandong Xinhua Manufacturing: SWOT Analysis\n\nTable 3.118 Siegfried Details\n\nTable 3.119 Siegfried Pharmaceutical Manufacturing Facilities Details, 2018\n\nTable 3.120 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2013-2018\n\nTable 3.121 Siegfried: SWOT Analysis\n\nTable 3.122 Teva API Details\n\nTable 3.123 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017\n\nTable 3.124 Teva API SWOT Analysis\n\nTable 3.125 Therapure Biopharma Details\n\nTable 3.126 UPM Pharmaceuticals Details\n\nTable 3.127 Vetter Details\n\nTable 3.128 Vetter Pharmaceutical Facilities\n\nTable 3.129 Vetter: SWOT Analysis\n\nTable 3.130 Xcelience LLC Details\n\nTable 3.132 Piramal Pharma Solutions Details\n\nTable 3.133 Piramal Pharma Solutions: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019\n\nTable 3.134 Zhejiang Hisun Pharmaceuticals Details\n\nTable 3.135 Zhejiang Hisun Manufacturing: SWOT Analysis\n\nTable 3.136 Zhejiang Huahai Pharmaceuticals Details\n\nTable 3.137 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.138 Zhejiang Huahai Contract Manufacturing: SWOT Analysis\n\nTable 3.139 Cambrex Corporation Details\n\nTable 3.140 Cambrex Corporation: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.141 Cambrex Corporation: SWOT Analysis\n\nTable 3.142 WuXi Tech Details\n\nTable 3.143 WuXi Tech: SWOT Analysis\n\nTable 3.144 WuXi Tech Details\n\nTable 3.145 Biocon: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.146 Biocon (Syngene International): SWOT Analysis\n\nTable 3.147 Strides Details\n\nTable 3.148 Strides: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018\n\nTable 3.149 Stride: SWOT Analysis\n\nTable 3.150 biophore India Pharmceutical Limited Details\n\nTable 4.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017"
    }
}